Innovative New Project to Help Provide Evidence-based Data for Behavioral Health Drug Discovery
Today Owl announced that Holmusk, a leading global data science and digital health company, will collaborate with Owl to enable improvements in real-world data for patients with major depressive disorder which could accelerate the process of finding new treatments for these patients.
The collaboration will leverage real-world data from Owl’s advanced measurement-based care platform and Holmusk’s proprietary natural language processing models. The insights gained from this project could be used to help accelerate the drug discovery process for new depression treatments.
“We look forward to working with Owl on this project, which underscores our belief in the role real-world data will play in transforming behavioral health,” said Nawal Roy, Holmusk Founder and CEO. “With our natural language processing models combined with Owl’s data insights we can take steps toward improving outcomes and accelerating the drug development process for behavioral health.”
“Holmusk and Owl share a strong commitment to using evidence-based data to serve the behavioral health market,” said Eric Meier, President and CEO of Owl. “This collaboration will help to improve care for patients with depression and deliver the insights that could result in new and improved treatment options for them.”
Owl gives behavioral health organizations better data, better insights, and better outcomes with its data-driven, evidence-based solutions. Leading organizations, including Main Line Health, Amita Health, Inova Health, Polara Health, and Aurora Mental Health Center, rely on Owl to expand access to care, improve clinical outcomes, and prepare for value-based care. Owl makes measurement-based care easy to engage patients, optimize treatment, improve care, reduce clinician burden, and capture data to optimize business performance. For more information on our transformational behavioral health solutions, visit owl.health.
Holmusk is on a mission to reinvent behavioral health and transform lives with Real-World Evidence and digital innovation. Headquartered in Singapore and New York, Holmusk generates evidence and builds digital solutions to advance behavioral health research, innovation, and care.
NeuroBlu, Holmusk’s flagship product, synthesizes Real-World Data (RWD) with seamless analytic tools, enabling users to create actionable insights that drive behavioral health transformation. NeuroBlu is powered by an industry-leading and continually growing behavioral health clinical dataset, with over 20 years of data on over half a million patients and 20+ million encounters. Holmusk uses advanced proprietary analytics to enrich the data, with Natural Language Processing and predictive disease models designed specifically for behavioral health. Holmusk augments its data and analytic offerings with powerful digital solutions that enhance patient engagement, support disease self-management, and capture patient-reported outcomes to help guide clinical decisions and analytics. For more information, please visit www.holmusk.com.